Pipeline

A pipeline innovated by the global human crisis

Indivior is pioneering the development and discovery of treatment strategies for opioid use disorder and other substance use disorders.

Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder.

To learn more about our commercially launched products, please visit the products page.

As part of its development and discovery process, Indivior is evaluating molecules and drug candidates that are too early stage to be listed below.

 

Brand Name/Product Candidate

Preclinical

Phase 1

Phase 2

Phase 3

Regulatory Approval

Commercial Launch

 
 
 
 
 
 
 
  •  
    Treatment of Opioid Use Disorder

    INDV-6001* is a sustained-release LAI prodrug of buprenorphine

  •  
    Treatment for Opioid Use Disorder

    INDV-2000 selective orexin-1 receptor antagonist